UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Pfizer on Attractive Valuation

Loading...
Loading...
In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer
PFE
, and raised the price target from $31.00 to $33.00. In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.” Pfizer closed on Tuesday at $29.11.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsJefferies
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...